Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 10.71 USD 0.66% Market Closed
Market Cap: 452m USD
Have any thoughts about
Urogen Pharma Ltd?
Write Note

Gross Margin
Urogen Pharma Ltd

90.3%
Current
89%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
90.3%
=
Gross Profit
80.7m
/
Revenue
89.4m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
IL
Urogen Pharma Ltd
NASDAQ:URGN
449.3m USD
90%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country IL
Market Cap 449.3m USD
Gross Margin
90%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 315.2B USD
Gross Margin
67%
Country US
Market Cap 141.9B USD
Gross Margin
60%
Country US
Market Cap 116.4B USD
Gross Margin
78%
Country US
Market Cap 104.5B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Urogen Pharma Ltd
Glance View

Market Cap
451.9m USD
Industry
Biotechnology

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

URGN Intrinsic Value
30.4 USD
Undervaluation 65%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
90.3%
=
Gross Profit
80.7m
/
Revenue
89.4m
What is the Gross Margin of Urogen Pharma Ltd?

Based on Urogen Pharma Ltd's most recent financial statements, the company has Gross Margin of 90.3%.